Study finds vitamin E supplements may reduce blod clots in women
PHILADELPHIA A study published online at the American Heart Association’s journal Circulation web site Monday found that supplementation with vitamin E may reduce the risk of venous thromboembolism (blood clots) in women, and those with a prior history or genetic predisposition may particularly benefit.
The Women’s Health Study randomized 39,876 women 45 years of age to receive 600 IU of natural source vitamin E or placebo on alternate days.
During a median follow-up period of 10.2 years, VTE occurred in 482 women: 213 in the vitamin E group and 269 in the placebo group, a significant 21 percent hazard reduction.
The report suggested more research would be necessary before drawing any concrete conclusions, however.
Abbott starts correction on blood glucose meters
ALAMEDA Abbott has started a worldwide medical device correction for its Precision Xtra, Optium, ReliOn Ultima, Rite Aid, and Kroger blood glucose meters that were manufactured after Jan. 31, 2007.
If the meter is dropped on a hard surface, it may affect the screen’s readability. Risks of not being able to read the test results include hypoglycemia or hyperglycemia.
Abbott Diabetes Care discovered the problem during testing which found the meters’ display can be jarred or disconnected when dropped, thereby making it difficult to read the lot number or date information; in some cases it caused the screen to appear completely blank.
Adams celebrates 10-year anniversary
CHESTER, N.J. Adams Respiratory Therapeutics Tuesday morning announced that it will commemorate the 10th anniversary of its incorporation with a celebration for employees on Sept. 12 at Municipal Field (Gazebo Park) in Chester, New Jersey.
“On the occasion of this important milestone, I applaud our employees, whose talents and tireless efforts have fueled Adams’ phenomenal growth in the past several years,” stated Michael Valentino, Adams president and chief executive officer. “I’m proud of our accomplishments and I look forward to a second decade of success with multiple new product introductions and our planned expansion into the prescription respiratory market.”
Adams, best known for its Mucinex and Delsym cough and cold products and the nationwide Mr. Mucus consumer advertising campaign, commenced operations in Fort Worth, Texas in September 1997. In April 2004, the company relocated its corporate headquarters from Fort Worth to Chester. Adams currently employees nearly 500 people and its Chester facility houses more than 80 of its employees. The company has expanded its headquarter operations twice since relocating to Chester in 2004 and doubled its portfolio of marketed respiratory products this year.
Federal, state and local officials are scheduled to attend and participate in a ceremony recognizing Adams for its decade of success as a specialty pharmaceutical company focused on the treatment of respiratory disorders.
“I congratulate Adams Respiratory Therapeutics on its 10-year anniversary, and the tremendous growth and success that this company has achieved in such a short period of time,” stated Stanley Kosierowski, chief operating officer and senior vice president, business support, New Jersey Economic Development Authority. “It is New Jersey’s good fortune to have companies like Adams come to our state, where they create jobs, become good neighbors and corporate citizens, and continue New Jersey’s fine tradition of improving public health by providing important medicines for the entire nation.”
In August 2007, Adams was named to Deloitte & Touche’s prestigious Technology Fast 50 Program for New Jersey, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area. Adams was ranked No. 7 overall, based on achieving a revenue growth rate of 1,638 percent from 2002 to 2006.